Drug intelligence / Profile preview

PharmaBiome GvHD bacterial consortium

Development stage: Preclinical
Lead developer: PharmaBiome
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

PharmaBiome's GvHD bacterial consortium is an investigational live biotherapeutic product (LBP) consisting of a rationally assembled group of bacterial strains. Developed by the Swiss biotech PharmaBiome, the therapy is designed to treat or prevent Graft-versus-Host Disease (GvHD) in patients undergoing hematopoietic stem cell transplantation. The consortium aims to restore the diversity and functional balance of the intestinal microbiome, which is typically disrupted by intensive conditioning regimens and antibiotic use. By re-establishing a healthy microbial ecosystem, the treatment seeks to modulate the host immune system and reduce the inflammatory processes that drive GvHD. The strains are produced using a proprietary co-cultivation technology that ensures the stability and functional synergy of the consortium.

Other names: Bacterial Consortium (GvHD)PharmaBiome microbiome therapy for GvHD

Beyond the preview

Go deeper on PharmaBiome GvHD bacterial consortium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PharmaBiome GvHD bacterial consortium.

Explore the full profile